Reshape Lifesciences (Reshape Lifesciences) Days Sales Outstanding : 87.75 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Days Sales Outstanding?

Reshape Lifesciences's average Accounts Receivable for the three months ended in Dec. 2023 was $1.91 Mil. Reshape Lifesciences's Revenue for the three months ended in Dec. 2023 was $1.98 Mil. Hence, Reshape Lifesciences's Days Sales Outstanding for the three months ended in Dec. 2023 was 87.75.

The historical rank and industry rank for Reshape Lifesciences's Days Sales Outstanding or its related term are showing as below:

RSLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.13 Med: 80.73 Max: 422.73
Current: 84.89

During the past 13 years, Reshape Lifesciences's highest Days Sales Outstanding was 422.73. The lowest was 38.13. And the median was 80.73.

RSLS's Days Sales Outstanding is ranked worse than
70.38% of 807 companies
in the Medical Devices & Instruments industry
Industry Median: 64.21 vs RSLS: 84.89

Reshape Lifesciences's Days Sales Outstanding increased from Dec. 2022 (64.70) to Dec. 2023 (87.75).

Reshape Lifesciences Days Sales Outstanding Historical Data

The historical data trend for Reshape Lifesciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Days Sales Outstanding Chart

Reshape Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

60.63

108.48

72.93

81.10

80.73

Reshape Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															64.70	85.88	82.99	87.40	87.75

Competitive Comparison of Reshape Lifesciences's Days Sales Outstanding

For the Medical Devices subindustry, Reshape Lifesciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reshape Lifesciences's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Days Sales Outstanding falls into.

Reshape Lifesciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Reshape Lifesciences's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (2.18	+	1.659)	/	2 )	/	8.678	*	365
=	1.9195					/	8.678	*	365
=	80.73

Reshape Lifesciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (2.153	+	1.659)	/	2 )	/	1.982	*	365 / 4
=	1.906					/	1.982	*	365 / 4
=	87.75

Reshape Lifesciences (NAS:RSLS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Reshape Lifesciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Reshape Lifesciences (Reshape Lifesciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Calle Amanecer, San Clemente, CA, USA, 92673

Website

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Executives

Thomas Stankovich	officer: Chief Financial Officer	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey	director, officer: President and CEO	2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy	director	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee	director	C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford	director	7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald	officer: Chief Retail Officer	C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt	officer: Vice President of Marketing	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr	10 percent owner	467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022